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Pump failure, ranging from ventricular dysfunction to
acute cardiogenic shock, is now the leading cause of
cardiac death. Efforts at temporary mechanical or phar-
macologic support of the heart have been largely un-
successful so that attention is now directed toward pre-
vention of ventricular failure and limitation of myocardial
infarct size or even outright prevention of infarction
itself. In particular, attention has been refocused on ear-
lier reperfusion efforts with streptokinase.
The effect of thrombolysis in acute myocardial in-
farction on enzymatic infarct size, left ventricular func-
tion and early mortality wasstudied in subsets of patients
in a randomized trial (Netherlands Interuniversity Car-
diology Institute). Early thrombolytic therapy with
intracoronary streptokinase (152 patients) or with intra-
coronary streptokinase preceded by intravenous strep-
tokinase (117 patients) was compared with conventional
treatment (264 patients). All 533 patients were admitted
to the coronary care unit within 4 hours after onset of
symptoms indicative of acute myocardial infarction. Of
the patients eligible for this detailed analysis, 245 were
allocated to thrombolytic therapy and 243 to conven-
tional treatment. Early angiography was performed in
212ofthe 245patients allocated to thrombolytic therapy.
In the last two decades , coronary care units have made it
possible to recognize and treat in time previously fatal ar-
rhythmias during the acute stage of myocardial infarction.
This has reduced the in-hospital mortal ity rate from ± 30%
to < 15%. At the same time, pump failure, ranging from
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Patency of the infarct-related artery was achieved in 181
patients (85%). Enzymatic infarct size, measured from
cumulative alpha-hydroxybutyrate dehydrogenase re-
lease, was smaller in patients allocated to thrombolytic
therapy (median 760 versus 1,179 U/liter in control sub-
jects, p = 0.0001). Left ventricular ejection fraction
measured by radionuclide angiography before discharge
was higher after thrombolytic therapy (median 50% ver-
sus 43% in control subjects , p =0.0001). Twelve month
mortality was lower in patients allocated to thrombolytic
therapy (8% versus 16% in the control group, p < 0.01).
In multivariate regression analysis infarct size limita-
tion, improvement of left ventricular ejection fraction
and 3 month mortality were predicted by IST, time from
onset of symptoms to admission and Killip class at ad-
mission. Thrombolysis was most useful in patients ad-
mitted within 2 hours after onset of symptoms and in
patients with a IST segment of 1.2 mV or more. On the
other hand, no beneficial effects of streptokinase on en-
zymatic infarct size, left ventricular function or mor-
tality were observed in the subset of patients with IST
less than 1.2 mV, admitted 2 to 4 hours after onset of
symptoms.
(J Am Coli CardioI1987;9:1375-84)
ventricular dysfunction to acute cardiogenic shock , has be-
come the leading cause of cardiac death . Because efforts at
temporary support of the heart mechanically or through
pharmacologic means have been largely unsuccessful , at-
tention is now directed toward limitation of myocardial in-
farct size or even outright prevention of infarction itself.
Although experimental data with a variety of pharmacologic
agents seemed promising, recent large scale clinical trials
with the early administration of beta-adrenergic blockers ,
such as the Metropol in Acute Myocardial Infarction (MIAMI)
trial (I) (also the ISIS 1 trial, Sleight, personal communi-
cation), and of calcium antagonists (2-6) have shown no
0735-1097/87/$3 .50
Figure 1. Curvilinear relation between the rest left ventricular
(LV) ejection fraction at discharge and I year mortality after myo-
cardial infarction. This relation has been found by many authors
(69-71). If one could move the immediate postinfarct ejection
fraction from, for example, 30 to 45% or from 45 to 60%, the
gains in I year survival (85 to 95%) appear to be impressive.
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Table 1. In-Hospital Clinical Course (data from Netherlands
study [9])
Control Thrombolysis
Group Group
(n = 264) (n = 269) P Value*
Hospital mortality (14days) 26 14 0.05
Recurrent infarction (14 days) 9 12
Angina pectoris 55 57
Heart failure in coronary care unit
Mild 55 54
Severe 12 10
Shock 24 13
Dopamine/dobutamine 42 26 0.03
treatment
Respiratory support II 6
Intraaortic balloon pump 10 16
Heart failure in 53 37 0.05
convalescence
Ventricular fibrillation 61 38 0.01
Pericarditis 46 19 0.0004
Bleeding 7 53 0.0001
Coronary angioplasty 9 59t
Bypass surgery 16 29
major reduction in mortality. This has helped to refocus
attention on earlier reperfusion efforts with streptokinase, a
powerful thrombolytic agent. The relevance of attempts to
improve left ventricular function by reducing the amount of
tissue lost to infarction is evident when one considers the
curvilinear relation between postinfarction left ventricular
ejection fraction at rest, a general expression of left ven-
tricular function and 1 year mortality rate (Fig. 1). It also
shows the benefits that may be expected if ventricular func-
tion can be maintained or improved.
Role of Coronary Thrombosis
in Myocardial Infarction
The causal role of thrombosis in acute myocardial in-
farction has long been a matter for debate (6). Although
since Herrick's days it had been assumed that thrombosis
was always the cause of an infarction, careful postmortem
studies in the I960s cast doubt on this theory because many
patients showed infarction without complete coronary ob-
struction. Some researchers postulated, therefore, that
thrombosis was the sequel of infarction. Such theories, based
on postmortem examinations, were corrected through the
detailed anatomic studies of Fulton et al. (7), which were
corroborated by DeWood et al. (8), whose coronary arte-
riographic studies in the first few hours after myocardial
infarction demonstrated that thrombosis was present in nearly
all cases. The latter authors studied 517 patients within 4
hours after onset of symptoms and found a complete ob-
struction in 86% of cases. These data were confirmed in the
recent large trial carried out by the Netherlands Interuni-
versity Cardiological Institute (9), which indicated complete
obstruction in 84% of 264 patients who were randomized
* Only values <0.05 are reported. t Coronary angioplasty was per-
formed more frequently in the thrombolysis group, when the 46procedures
immediately after thrombolysis are included. No significant differences
were observed except for pericarditis and bleeding.
to early angiography and intracoronary thrombolysis (Table
1). Similar data were reported by others (10-14).
Recently, Falk (15) identified a ruptured atheromatous
plaque as the cause of 40 of 51 recentcoronary artery thrombi.
This finding points to the significance of a ruptured athero-
sclerotic plaque in the genesis of sudden coronary artery
obstruction, either by hemorrhage into an expanding plaque
or by serving as a nidus for intraluminal platelet aggregation.
Davies and Thomas (6) found that the same mechanism was
operative whether the clinical outcome was unstable angina,
myocardial infarction or sudden death.
Relevance to coronary thrombolysis. These observa-
tions bring four fundamental concepts into focus: 1) angi-
ography can be carried out in acute myocardial infarction
without major risks; 2) thrombosis is present in the majority
of patients studied within the first few hours after symptoms;
3) the prevalence of complete obstruction declines as the
time after the onset of symptoms lengthens; and 4) residual
obstruction in and around the plaque remains a major prob-
lem even after successful lysis. Indeed, total obstruction
was found in only 60% of cases when the interval after the
onset of symptoms exceeded 6 hours, corresponding to the
pathologic observations that, on average, complete obstruc-
tion was present in only half of the cases studied 6 to 24
hours after the onset of symptoms or death. It is therefore
likely that limitation of infarct size by a strategy aimed at
relief of obstruction will be successful only in patients who
present themselves for therapy within hours after onset of
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symptoms in an early stage of acute myocardial infarction,
and that many patients may require balloon dilation even
after successful lysis. Indeed, the experimental evidence of
Sobel et al. (14) demonstrates that only reperfusion within
4 hours will limit the ultimate infarct size and achieve return
toward normal cardiac function and metabolism. Recent
overwhelming clinical evidence (9-28) confirms the effi-
cacy of early reperfusion, because the greatest reduction in
mortality and greatest limitationof infarct size were achieved
in patients in whom lysis took place within 2 hours and who
had coronary angiography as part of the procedure (9-11).
Which Proof is Available: Intravenous and
Intracoronary Studies in Humans
Early reperfusion studies. The feasibility of rapid dis-
solution of intracoronary thrombi by systemic or selective
infusion of thrombolytic substances was convincingly dem-
onstrated in experimental series and in clinical pilot studies
almost 30 years ago (16-21). This led to widespread trials
of intravenous administration of streptokinase, given in
varying doses and at varying time intervals, mostly with
disappointing or nonsignificant results. This apparent lack
of efficacy can now be explained in part by study inade-
quacies-too few patients, poor patient selection, inappro-
priate evaluation techniques and old-fashioned statistical de-
sign-but mainly by (too) late administration of streptokinase.
In particular, no attempts were made to prove patency of
the infarct-related artery by angiography or to measure in-
farct size. The older experience should therefore be elimi-
nated from current considerations, although Yusuf et al.
(22) concluded from a pooled analysis of some 6,000 pa-
tients in 24 randomized trials with intravenous streptokinase
that a reduction in the odds of death by 22 ± 5% can be
deduced, despite the nonsignificant results achieved in most
individual studies.
Systematic efforts at restoration of anterograde flow after
intracoronary administration were not introduced into clin-
ical practice until 1979 by Rentrop and coworkers (21,25)
in Germany. Since then, we have witnessed a dramatic
increase in the number of patients with acute ischemic car-
diac disorders who have been treated by intracoronary strep-
tokinase infusion (26-28). The advantages of early intra-
venous administration combined with intracoronary lysis
and aggressive follow-up treatment of residual coronary ar-
tery obstruction with coronary angioplasty or bypass surgery
to optimize coronary blood flow have recently been ade-
quately investigated. The striking benefits are entirely con-
sistent with experimental evidence (14,29).
Factors influencing outcome of thrombolytic therapy. In
our editorial in 1982 (30), in which the published data up
to that year were reviewed, Rentrop and I voiced various
notes of caution against excessive early enthusiasm. We
pointed to the main factors that could positively or nega-
tively influence the ultimate outcome. These included the
need to know the time interval between the onset of symp-
toms and reperfusion, the extent of restoration of myocardial
function in the region perfused by the infarct-related artery,
the functional availability of collateral flow, the best route
and optimal dose of the thrombolytic agents, the best agent
and its side effects and the degree to which the usual se-
quelae of myocardial infarction, such as subsequent angina,
reinfarction and death, could be reduced in the treatment
group when compared with a control group randomly as-
signed to conventional treatment. These arguments were
recently repeated by Yusuf et al. (22), although their con-
clusion that giant trials with thousands of patients are needed
to solve these questions is debatable. In fact, the recent
GISSI study (23) (Table 2) has clinched the argument by
showing the greatest reduction in early mortality in the 52%
of the 11,483 randomized patients who reached the hospital
in time to receive their 1.5 million units of streptokinase
Table 2. Mortality by Hours From Onset of Symptoms (data from GISSI trial [23])
Mortality (%)
SK C Risk Ratio Total Mortality (%)
Hours (deaths/n) (deaths/n) p Value 95% (CI) (deaths/n)
<3 9.2 12.0 0.0005 0.74 10.6
(278/3,016) (369/3,078) (0.63 to 0.87) (647/6,094)
>3 to 6 11.7 14.1 0.03 0.80 12.9
(217/1,849) (254/1,800) (0.66 to 0.98) (471/3,649)
>6 to 9 12.6 14.1 NS 0.87 13.3
(87/693) (93/659) (0.64 to 1.\9) (\80/1,352)
>9 to 12 15.8 13.6 NS 1.19 14.6
(46/292) (41/302) (0.75 to 1.87) (87/594)
<I 8.2 15.4 0.0001 0.49 11.8
(52/635) (99/642) (0.34 to 0.69) (\51/1,277)
The data show clearly that the patients treated early «3 hours) show the best outcome. C = controls; CI = confidence interval; n = no. of patients;
SK = streptokinase.
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within 3 hours after the onset of symptoms even though the
drug was given intravenously. Much less benefit was dem-
onstrated in those arriving later. A similar message came
from the Jerusalem ambulance study (24) in which myo-
cardial salvage was demonstrated in those treated with in-
travenous streptokinase within 1.5 hours after onset of
symptoms.
As our concepts regarding the time course of ischemia
evolve, particularly our views of the role of the available
collateral supply and the load existing on the heart at the
time of onset of coronary obstruction, we should be able to
direct further therapy or interventions toward specific ad-
ditional derangements. The infusion of beta-receptor block-
ers when excessive tachycardia or elevated blood pressure
exists, calcium entry blockers when ischemia and spasm are
still predominating (31) or "scavengers" of unwanted me-
tabolites, such as oxygen radicals released during the re-
perfusion phase, all may be required in addition to lysis of
the obstruction. In fact, they may playa major role in
treatment because reperfusion, particularly when carried out
late, can induce myocardial damage that may be as great
as the ischemia-related necrosis.
More recent studies in thrombolysis. Returning to the
question posed in our editorial (30): what have we learned
from the smaller series and incidental observations in the
years since 1980? Most importantly, early recanalization,
whether by guide wire alone (21) or by clot lysis with
streptokinase (9-14,16-28,32,33), urokinase or recombi-
nant tissue plasminogen activator (rt-PA) (34-37) has been
shown to limit infarct size (29,32,33), preserve cardiac func-
tion (38-46) and reduce early as well as late mortality
(9,47-50). Although Schaper (29) and others (38-41) have
Figure 2. The interval between interruption of coronary flow and
the extent of limitation of infarct size (modified from the data by
Schaper [29]). Myocardial infarct size depends on the species
studied. Note that humans have a declining yield when more than
2 hours have elapsed since interruption of blood supply. If we
were to suppose that thrombolysis would occur 30 minutes earlier
when given at home or in the ambulance, the ultimate infarct size
could be limited by a further 15%.
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confirmed in many animal models that, after 6 hours of
complete ischemia, the amount of salvageable myocardium
is insignificant, no animal model can completely mimic the
human situation (29,39-41) (Fig. 2). A case can therefore
be made to institute therapy after the sixth hour if ischemic
signs are still present. Nevertheless, most data support the
thesis that reperfusion must be established soon after oc-
clusion, because no major beneficial effects can be expected
beyond 3 to 4 hours after the onset of ischemia. Van der
Giessen et al. (41) in our laboratory demonstrated in the pig
that, after thrombosis, myocardial infarction could be averted
only when a thromboxane antagonist had been given before
the induction of thrombosis. In the same model, coincident
therapy with nifedipine favorably altered capillary perfusion
(beta-receptor blockade and oxygen scavengers are other
options), although it did not change the extent of necrosis.
Thus, it remains possible that the time window for sal-
vage can be widened to beyond 3 and perhaps up to 12
hours with additional pharmacologic agents. Although data
from the pooled analysis by Yusuf et al. (22) suggest that
some statistical benefit cannot be excluded when treatment
is started late, the numbers are not convincing and recent
data from the GISSI trial (23) indicate that lytic therapy
increases mortality when treatment is begun later than 9
hours after the onset of symptoms (Table 2):Several authors
(42-44) found that, whereas the extent of salvage is much
less when therapy is started later than 4 hours after the onset
of symptoms, late recanalization may still result in some
improvement, particularly in patients who have collateral
flow demonstrable by acute angiography. It is likely that in
these patients, the evolution of "stuttering myocardial ne-
crosis" is slowed when collateral flow is enhanced early
on.
Intravenous plus intracoronary thrombolysis. The Neth-
erlands data (9) have also shown that the best improvement
in cardiac function, smallest infarct size and lowest mortality
occurred in the subset of 117 patients in whom intracoronary
lysis was preceded by early intravenous administration of
streptokinase. In these patients, lysis was achieved a median
of 3 hours after the onset of symptoms whereas the intra-
venous bolus of 0.5 million units of streptokinase reached
the majority within 2 hours. Angiography before the start
of subsequent intracoronary streptokinase treatment showed
a patent coronary artery in less than half of these patients,
however. Thus, improved outcome was seen in cases with
persistent obstruction of the main infarct-related vessel. This
finding supports the view that lytic therapy may work not
only through relief of obstruction of the main infarct-related
vessel, but also through improved rheology and reduced
viscosity benefiting the collateral bed. This hypothesis is
supported by the finding that cardiac enzyme washout was
highest in those patients who were treated earliest but also
occurred in those in whose infarct-related vessel remained
closed. Another lesson we have learned is that although the
JACC Vol. 9, No.6
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intravenous plus intracoronary streptokinase group from the
Netherlands trial (9) and the GISSI data (23) confirm the
thesis recently proposed by Verstraete (45), that intravenous
administration of a lytic agent is "the only way," the initial
successful reperfusion will not be sufficient when signs of
ischemia persist or return. This will occur in many, if not
half, of the cases because of the underlying atheromatous
lesion (3,7,12,15,46). Thus, the "only way" has to be
modified by preparation to maintain or establish complete
recanalization in those demonstrating initial success.
ST c1.2
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Figure 4. Median values and quartiles of enzymatic infarct size
in four subsets of patients in both treatment groups. Infarct size
limitation is most prominent in patients with IST ~ 1.2 mV, and
in patients admitted within 2 hoursafteronsetof symptoms. Hatched
bars, lysis; open bars, controls. ST = sum of ST segment ele-
vation on the ECG at admission (mV); HBDH = alpha-hydroxy-
butyratedehydrogenase; Strepto = streptokinase. (Reproducedby
permission of the AmericanHeart Association, Inc. from Vermeer
F, et al. [46].)
months) was achieved in the subgroup of 36 cases in which
coronary lysis was combined with angioplasty (51). In-
cluding nonrandomized patients as well, we find just one
death in 98 cases in 1 year. This observation strongly un-
derpins the hypothesis that early but complete revasculari-
zation is essential by whatever means it is achieved. Fur-
thermore, the best overall results, as assessed by preserved
left ventricular function, infarct size limitation and reduction
in shock, cardiac failure, ventricular fibrillation and peri-
carditis, were found in the group assigned to thrombolysis
within 2 hours after the onset of symptoms (46) (Fig. 3).
In addition, enzyme release (alpha-hydroxybutyrate de-
hydrogenase) was 30% lower in the treated group, indicating
a smaller size of the ultimate infarct. This was also reflected
in a marked improvement in left ventricular ejection frac-
tion, which was significantly higher, by 7% overall, in the
treated compared with the control group (53% versus 46%).
In the latter group, furthermore, end-diastolic and end-sys-
tolic volumes were normal. Again, the best results were
seen in patients with anterior wall infarction treated within
2 hours (Fig. 3 to 6).
Role in unstable angina. Of interest are other data col-
lected in the same time span at our center (52) in patients
with unstable angina, a condition that may be considered a
precursor of acute myocardial infarction. In 60 of 217 pa-
tients who had been refractory to intense, often triple, phar-
macologic treatment and who were aggressively treated early
with coronary angioplasty, the I year mortality rate was
low (1%), without occurrence of subsequent infarction. This
again indicates the desirability of clearing up the obstruction
when postinfarction symptoms of ischemia persist after
vasodilation or thrombolysis. Similar data have been found
71
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The Ultimate Aim: Reduce Mortality to a
Few Percent
50%
Achieving early and complete revascularization. Evi-
dence for reduced mortality is available in the Netherlands
Interuniversity Cardiology Institute Trial (9), in which 264
of the 533 patients were allocated to conventional treatment
in the coronary care unit and 269 to attempted reperfusion.
Of these 269 patients, 152 were assigned to streptokinase
by the intracoronary route only, and 117 received 500,000
units of streptokinase intravenously before intracoronary
administration. It was shown on an intention to treat prin-
ciple that mortality at 14 days was 5% (14 of 269) in the
group assigned to thrombolysis versus 9% (25 of 264) in
the group assigned to conventional therapy, whereas at a
median of 8 months, it was 9% versus 16%, a highly sig-
nificant reduction in mortality (p < 0.01) (Table 1). How-
ever, the mortality in the group receiving intravenous with
intracoronary streptokinase was even lower than that in the
overall group, and the lowest mortality (one death in 20
Figure 3. Results of acute angiography in subsets of patients;
acute catheterization was offered to patients allocated to throm-
bolytic therapy only. Final patency rate was lower in patients
admitted 2 to 4 hours after onset of symptoms compared with
patients admitted within 2 hours after onset of symptoms. IC =
intracoronary; IV = intravenous; ST = sum of ST segment el-
evation on the ECG at admission (mV). Crossed-hatched area,
occluded before and after lysis; hatched area, occluded before,
patent after lysis; open area, patent before and after lysis. (Re-
produced by permission of the American Heart Association, Inc.
from Vermeer F, et al. [46].)
100%
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rt-PA, perhaps even exceeding the results obtained with
intracoronary streptokinase. The earlier thesis by Verstraete
(45) that the intravenous route of early drug administration
is the only realistic one is again to be amended becau se,
even with this new agent , a significant subset of patients
will require further therapy of "critical narrowing," par-
ticularly in the light of recent evidence (60) indicating that
the short duration of rt-PA activit y may lead to higher reoc-
elus ion rates after initial success. This , in turn , strengthens
our previous arguments (9,30 ,51) that , if relief of ischemic
symptoms and signs is not complete within 2 to 4 hours
after administration of intravenous rt-PA, or of any other
agent, intracoronary manipulations remain mandatory be-
cause myocardium is jeopardized from the first few minutes
of ischemia (14,29,38,39,50) . The short duration of action
of rt-PA is an advantage, not only because of the limited
suppression of systemic fibrinolysis, but also because of the
increased opportunity this provides for surgical intervention
when obstruction persists on the basis of the underlying
residual atheromatous lesion and coronary angioplasty does
not offer a solution. Coincident therapy with prostacyclin
stimulatory agents or thromboxane blockers (41) may well
improve this strategy.
Recommendations Under Optimal Conditions
Because the United States (13,27) , Italian (23) and Neth-
erlands (9,46 ) trial results are all based on the "intention
to treat principle" and on a random assignment procedure,
early reperfusion of the obstructed coronary artery in acute
myocardial infarction can now be recommended in health
care systems in which certain essential conditions can be
met. These conclusions can be derived even from nonran-
domized data (47-50). The conditions are rapid referral and
transport in (peri)urban populations with rapid access to a
catheterization laboratory that has staff trained in these pro-
cedures. In Western Germany this is now the case for 66%
of the eligible population (47) and in the Netherlands at
least 75 0/.0 have access to such facilities provided adequate
referral arrangements have been made . Even in the United
States , analys is of subsets in the Western Washington trial,
the only other large scale , randomized trial (27), has indi-
cated that similar reductions in mortality rates could be
achieved in patients admitted within 4 hours . Added to these
are nonrandomized studies such as those carried out in Ger-
many (Aachen, 461 patients [47] ; Mainz and Heidelberg, a
total :t 700 patients [48]; Hamburg and Berlin, > 1,000
patients [49]) and in France (50) (:t 1,000 patients with
access for 55% of the eligible population); these studies all
indicate that in patients in whom early reperfusion was
achieved, a marked reduction in mortality with improvement
in ventricular function could be demonstrated, particularly
when reperfusion was associated with early efforts at "per-
manent" recanalization.
ST c1.2
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Figure 5. Median values and quartiles of left ventricular ejection
fraction at 10 to 40 days measured by radionuclide angiography
in four subsets of patients in both treatment groups. Improvement
of ejection fraction is most prominent in patients admitted within
2 hours after onset of symptoms. Hatched bars, Lysis; open bars,
controls. Abbreviations as in Figure 4. (Reproduced by permission
of the American Heart Association, Inc. from Vermeer F, et aJ.
[46].) .
in nonrandomized observations (47-50). It is the underlying
atheromatous obstruction, regardless of the presenting syn-
drome, that must be reduced early (3,7, 21,30). In this re-
gard , we underline the comment by Verstraete (45) that
"critical narrowing continues to be a threat to the patient,
even after early reestablishment of anterograde flow. "
Newer thrombolytic agents. The entire field has been
enormously stimulated by the development of improved agents
to lyse the thrombus. In the Edward Kowalski memorial
lecture in 1979, Collen (53) presented evidence that plas-
minogen activation could occur in several different path-
ways. Shortly afterward Collen and Verstraete (54) argued
in favor of tissue-type plasminogen activator (rt-PA) for
systemic thrombolytic therapy and 'van der Werf et al. (35)
demonstrated its beneficial effect in humans.
Verstraete et al. (37) reported for the European Coop-
erative Study Group in 1985 that , in 64 patients treated with
rt-PA , the frequency of coronary patency was higher (72%)
than ~fter intravenous streptokinase therapy (55%). A more
recent study (55) shows that when rt-PA was compared with
placebo by angiographic documentation , patency was achieved
in 38 (61%) of 62 patients receiving rt-Pa compared with
only 13 (21%) of 62 patients receiving placebo, although
there was a 6 hour delay in onset of therapy. The United
States TIMI trial (36) also showed the superiority of rt-PA
over streptokinase, although the interval between the onset
of symptoms and therapy seemed unduly long to avoid
" jeopardized," blighted and necrotic myocardium (56).
Intravenous tissue-type plasminogen activator (rt-PA).
These and other trials currently in progress promise that the
results based on current evidence from "the best" intra-
venous and intracoronary streptokinase trials (57-66) can
be expected to be even better with intravenous infusion of
JACC Vol. 9, No.6
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The Total Experience Indicates and
Warrants the Following New Positions for
the Medical Profession
Figure 6. Three month mortality , expressed as a percentage, in
four subsets of patients in both treatment groups. Reduction in 3
month mortality is most prominent in patients with IST 2: I. 2
mV. Abbreviations as in Figure 4. (Reproduced by permission of
the American Heart Association, Inc. from Vermeer F, et at. [46]. )
Immediate Future
Therapeutic complications. Although these conclu-
sions indicate that, to reduce unnecessary death, early re-
perfusion must be recommended in all patients with sus-
pected acute coronary artery obstruction in whom no
contraindications exist, many practical restrictions remain
(30,61,63). The need for cardiac catheterization in perhaps
> 50% of cases to verify the quality and the extent of re-
canalization, particularly in patients with persistent signs of
ischemia, can be met only in appropriately equipped and
strategically locatedcenters (47,63) whose numberwill have
to be increased. Furthermore, the inevitable delays in rec-
ognizing symptoms, the need to call the appropriate au-
thority or the physician, the delay in transport and the limited
availability of catheterization laboratories or operating rooms
on permanent standby will initially influence the utility of
such an approach. Therefore, if a simple intravenous throm-
bolytic agent were widely available (such as human tissue
rt-PA, which is currently a leading candidate) or an im-
proved streptokinase derivative, if it were to be proved as
effective (BRL.26922), together with aggressive anti-isch-
emic therapy with cardioprotective agents (such as the com-
binationof an effective beta-receptorblocker with a calcium
intravenous streptokinase. Although reocclusion rates
with rt-PA are higher than with streptokinase(55), early
coronary angioplasty has been advocated and proved
successful (57). It may well be the combination of the
future, when rt-PA becomes generally available as cur-
rent trials are completed.
8. It has been shownthat whenresidual stenosis is detected
by clinical signs (such as recurrence of pain, ST seg-
ment elevation or increases in creatine kinase release)
early coronary angioplasty or surgical bypass grafting
can achieve optimal recanalization, thus reducing I year
mortality to a few percent ultimately.
9. Early reperfusion will lead to smaller infarct size (58,59)
and maintained left ventricular function (60), thus ex-
plaining the much improved prognosis and survival rates
(9).
10. Early coronary angioplasty and bypass surgery without
prior pharmacologic lysis have shown similar benefits
in selected centers, but they are costly and applicable
only to patients who can reach a catheterization labo-
ratory within 2 hours and who have not had prior ther-
apy.
II . It will be more a matterof rearrangingexisting facilities
(rapid detection, referral, admission) than of finding
the optimal reperfusion strategy that will ultimatelyde-
cide whether the full benefits of this new therapeutic
aproach can be enjoyed by a majority of patients with
acute infarction.
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I. Thrombus formation is present in ± 85% of all patients
who present within the first 4 hours after the onset of
acute myocardial infarction. It is the cause of infarction.
2. Although the thrombus may lyse spontaneously, this
usually occurs after the fourth hour, by which time the
interruption of blood supply has typically led to per-
manent damage of myocardial tissue, so that we cannot
afford to wait and see.
3. Coronary angiographyand intracoronary manipulations
can be carried out in centers with properly trained per-
sonnel without undue complications in those patients
in whom ischemia returns or persists after previously
initiated intravenous lytic therapy.
4. Intracoronary streptokinase, preferably preceded by in-
travenous streptokinase, is currently the most effective
method to lyse a thrombus provided it is administered
early after the onset of symptoms. It has halved the I
year mortality rate from 15.9 to 8.5% in the recent
Netherlands trial (Fig. 6).
5. Intravenous streptokinase, when given within 0 to 3
hours of onset of symptoms, can achieve similar results
(GISSI trial).
6. Intracoronary administration must therefore be consid-
ered a sequel to intravenous therapy when recanaliza-
tion by the intravenous route, on average achieved in
only 50 to 55% of cases, has not alleviated ischemia.
Although rheologic factors (opening of collateral ves-
sels, decreasedviscosity)may be beneficial, even when
the main obstruction has not yet been resolved, they
are of secondary importance.
7. The reported data for recombinant tissue plasminogen
activator (rt-PA) thus far indicate it to be superior to
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antagonist [on theoretical grounds, the combination of ate-
nolol with nifedipine which is the leading contender] [31,67])
or with an afterload-reducing agent (such as captopril), then
an ambulance-based early treatment system (68) will gain
further in attractiveness. If rt-PA, which is a natural activator
of the fibrinolytic system and is now produced by a recom-
binant DNA technique, were to become available on a large
scale and if the current initial trials that yield up to 70%
reperfusion within 1 to 4 hours after intravenous adminis-
tration of rt-PA were to show the same improvement in left
ventricular function and reduction in death rates, as the best
streptokinase trials now do, it would certainly constitute a
major breakthrough and revolutionize the treatment of acute
myocardial infarction.
A European trial is now under way to judge its efficacy
on threegroups ofpatients withacutemyocardial infarction:
1) patients receiving conventional treatment with intrave-
nous rt-PA; 2) patients receiving intravenous rt-PA followed
by coronary angiography and, when needed, coronary an-
gioplasty; and 3) patients receiving conventional coronary
care unit treatment with placebo. End points are ventricular
function, infarct size and mortality.
Future treatment strategies. If results are positive, a
futuristic picture can be conceived of widespread admin-
istration of plasminogen activator combined with cardio-
protective agents in the first few hours after the onset of
acute myocardial infarction by the general practitioner or
ambulance service. On admission to the coronary care unit
within 6 hours (time having been gained by early intravenous
administration of the lytic agent), those patients with resid-
ual or returning ischemic signs of ischemia would be im-
mediately catheterized with the aim of permanent recanal-
ization by angioplasty or bypass surgery. The other, "cooled
off" patients would not need urgent intervention, although
on angiography many would be found to have severe ob-
struction which could be handled electively. Proof of the
efficacy of such a strategy lies in application of this scheme
to all patients suffering from acute myocardial infarction in
a given health region. The possibility of conducting such a
large scale approach must be available in cities the size of
Newcastle, Mainz, Rotterdam or Seattle with their "mod-
est" number of 300,000 to 600,000 citizens. Well organized
transport systems and properly distributed health care cen-
ters have already proved their value in reducing sudden death
in these cities and could serve as its basis.
The ultimate hope is that if, indeed, myocardial infarct
size can be limited or infarction avoided altogether with a
resultant halving of death rate, the cost savings, solely from
not incurring expensive postmyocardial infarction interven-
tion measures such as treatment of cardiogenic shock or
cardiac failure, could easily outweigh the modest increase
in initial costs required by early treatment (67). If this is
correct, both the quality and the duration of life after in-
farction could be increased at an acceptable cost.
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